Hepatotrophic effects of FK506 in dogs by Starzl, TE et al.
0041-1337/91/5101-0067$03.00/0 
TRANSPLANTATION 
Copyright Ii';' 1991 by Williams & Wilkins 
Vol. 51,067-070, No.1, January 1991 
Printed in U.S.A.. 
HEPATOTROPHIC EFFECTS OF FK506 IN DOGS! 
THOMAS E. STARZL/ KENDRICK A. PORTER, VINCENZO MAZZAFERRO, SATORU TODO, 
JOHN FUNG, AND ANTONIO FRANCAVILLA 
The Department of Surgery, University Health Center of Pittsburgh, University of Pittsburgh, and the Veterans Administration 
Medical Center, Pittsburgh, Pennsylvania; and the Department of Pathology, St. Mary's Hospital and Medical School, 
London, England 
Portacaval shunt (Eck fistula) in dogs causes hepato-
cyte atrophy and organelle disruption, as well as tripling 
of hepatocyte mitoses. After submitting dogs to this pro-
cedure, FK506 was infused into the tied-off left portal 
vein. The size, anatomic quality, and replication of he-
patocytes were enhanced in the portion of liver infused 
with FK506, with a significant spillover effect in the 
noninfused portion. These hepatotrophic qualities of 
FK506 may explain part of FK506's efficacy for the 
treatment of chronic liver rejection. Also, the observa-
tions support a trial with this drug for the treatment of 
autoimmune liver diseases because, in addition to turn-
ing off the immunologic genesis of such disorders, repair 
and regeneration of the damaged liver may be aug-
mented. Finally, these hepatrophic qualities are part of 
an emerging spectrum of biologic effects caused by drugs 
that may modulate the enzyme cis-trans peptidyl-prolyl 
isomerase (PPlase), the principal constituent of the cy-
tosolic binding sites of FK506, repamycin, cyclosporine, 
and presumably other immunosuppressive drugs as yet 
undiscovered. 
The "first pass" effect on the liver of orally administered 
drugs brought to the liver in high concentration via the portal 
vein has been difficult to assess. We have developed a model 
by which the direct hepatic action of substances such as insulin 
(1) and growth factors (2) can be studied in dogs. The agent 
under investigation is infused into the tied-off left main portal 
branch after portacaval shunt (Eck fistula) (1). The effects on 
the infused left hepatic lobes supplied by this branch can be 
determined and compared with those in the uninfused right 
hepatic lobes. 
FK506, a new orally administered immunosuppressive drug 
of the macrolide class, has been shown to stop both acute and 
chronic liver allograft rejection in humans more reliably and 
completely than has been possible before (3). In some of these 
patients, the recovery of the livers, even years after transplan-
tation, was so surprising that we suspected FK506 of having 
liver-restoring (hepatotrophic) qualities in addition to its ability 
to interrupt ongoing immunologic damage. In the present study, 
pronounced hepatotrophic consequences of FK506 have been 
documented with the canine Eck fistula model. The findings 
could explain some of the benefits observed in rejecting liver 
grafts "rescued" with FK506, and they could have therapeutic 
implications as well for the treatment of many hepatic diseases 
not involving transplantation. In addition, the findings con-
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tribute to a better understanding of the full spectrum of effects 
caused by drugs like FK506, rapamycin, and cyclosporine, 
which bind to cytosolic proteins that contain cis-trans peptidyl-
prolyl isomerase (PPlase)* and that affect the action of this 
enzyme. 
MATERIALS AND METHODS 
Twenty adult female beagle dogs underwent Eck fistula. After per-
forming a large side to side portacaval shunt, the left and right portal 
vein branches were ligated. A small infusion catheter was tied into the 
left branch and led through the abdominal wall and subcutaneously to 
a battery-charged infusion pump (Fig. 1) that was incorporated into a 
nonrestraining body cast. A constant infusion was started of the control 
or test fluids at the volume of 20-30 ml/day. Oral fluids and diet were 
allowed ad libitum. Four days later, the animals were administered 0.2 
mCi/kg (CHs-3H}-thymidine with specific activity of 80-90 Ci/mmol 
(New England Nuclear, Boston). Two hours later, the dogs were anes-
thetized and killed. 
Specimens were taken from 2 of the right hepatic lobes and 2 of the 
left lobes, fixed in 10% buffered formalin, and stained using standard 
hematoxylin-eosin staining techniques. Autoradiography was carried 
out using Ilford K5 nuclear track liquid emulsion and an exposure time 
of at least 30 days. The number of mitoses, as an index of hepatocyte 
regeneration, was determined by counting the number of 3H -thymidine-
labeled nuclei per 1000 hepatocytes. The size of individual hepatocytes 
(index of hypertrophy) was determined by tracing out a large number 
of midzonal liver cells projected on standard-thickness paper, cutting 
out the individual silhouettes, and weighing each (4). This method has 
been shown to be accurate for determining hepatocyte cell size and has 
been validated by planimetry and by studies of unicellular organisms, 
the size of which have been determined directly. In normal, unaltered 
dogs, about 1.6±OA mitosis per 1000 hepatocytes are present in the 
liver, and midzonal hepatocytes are about 0.17±0.01 size-units (2). The 
exceptional reproducibility of these values and the small standard 
deviations in experiments performed as long as 15 years apart make it 
easy to identify changes caused by operations such as Eck fistula, drugs, 
or other experimental variables. 
For studies of the organelles, small cubes of each hepatic sample 
were taken for electron microscopy. The tissue was postfixed in gluta-
raldehyde followed by osmic acid. After embedding in Polarbed 812 
resin, ultrathin sections were cut, stained with lead citrate, and exam-
ined in a Phillip's 300 electron microscope. Measurements of the 
organelles were made on electron micrographs by Loud's method (5). 
Results are expressed as mean ±SD. The Student's t test was 
employed in individual experimental groups to compare differences 
between right and left lobes or between groups. A P value less than 
0.05 was considered to be significant. 
RESULTS 
Infusion of the drug vehicle did not affect the hepatocyte 
atrophy typical of the Eck fistula liver or change the low-grade 
* Abbreviations: HSS. hepatic stimulatory substance; PPIase, cis-
trans peptidyl-prolyl isomerase. 
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hyperplasia (Table 1, vehicle controls). However, when FK506 
was infused into the left portal vein, atrophy of the left lobar 
hepatocytes was prevented in proportion to the dose, and the 
rate of mitoses was increased. These changes were significantly 
greater in the directly infused lobes at all doses, but even the 
noninfused lobes were significantly protected compared with 
the vehicle controls at the high FK506 doses (Table 1). 
Comparison of the ultrastructure of the left and right lobar 
hepatocytes showed that the hepatocytes exposed to infused 
FK506 were almost normal even at the smallest doses (Tables 
2 and 3). The amount of rough endoplasmic reticulum was 
restored relative to controls; in addition, dilatation and disrup-
tion of the cisternae were minimal. The number of microbodies, 
lysosomes, and small lipid-containing vacuoles were near nor-
mal levels in the FK506-infused lobes. The mitochondria in 
these lobes were neither enlarged (Table 3). nor abnormal. 
The changes in the hepatocytes in the right lobes did not 
differ greatly from those seen in the controls at low doses of 
FK506. However, at the 1 mg/kg/day dose, there was better 
preservation of the RER in the right lobes compared with right 
lobar hepatocytes in the vehicle controls (Table 2), and reduced 
lipid accumulation (P<OOl). At this high dose, the right lobar 
hepatocytes also had reduced microbodies (P=.07) and lyso-
zomes (P<05). 
There was no histopathologic evidence of drug toxicity in the 
lobes infused with FK506. Both with light and electron micros-
Pump 
FK-506 
FIGURE 1. The experimental method. 
copy, glycogen deposits were normal compared with the degly-
cogenated contralateral lobes. 
DISCUSSION 
Our experimental preparation should be useful as a surrogate 
model to test the effect on the liver of drugs given orally and 
absorbed into the splanchnic venous system. The principle of 
the model is to create the abnormal state caused by depriving 
the liver of its portal venous inflow, and to see what happens 
to the hepatic lobes supplied by the left portal vein when a test 
substance is directly infused into this vessel. If an agent has 
demonstrable effects on the portion of the liver that is infused, 
these can be compared with changes in the noninfused hepatic 
fragment that serves in each experiment as a control. From 
this comparison, assessment can be made not only of a drug's 
affect upon liver structure but also of its first-pass clearance. 
With insulin (1) and a cytosolic hepatic stimulatory substance 
(HSS) (2), the so called hepatotrophic effects of hyperplasia, 
hypertrophy, and maintenance of normal organelle structure 
that have been construed to signify hepatocyte health are found 
almost exclusively in the infused lobes. Some agents, such as 
glucagon, which have a powerful metabolic action on the liver 
have no hepatotrophic qualities that are demonstrable with this 
model (1 ). Thus, the fact that FK506 is hepatotrophic is seen 
as an unusual endowment. 
Although these hepatotrophic effects were similar to those 
caused by insulin and HSS (1, 2), FK506 had a somewhat 
greater spillover effect into the uninfused lobes. The unbal-
anced effect on the infused versus the non infused liver lobes 
suggests that most ofthe hepatrotrophic mechanisms are taking 
place within the liver, rather than systemically. It is thought 
that FK506 has no direct effect on isolated hepatocytes in 
culture (6). FK506 is metabolized exclusively by the liver (7). 
To the extent that its hepatrotrophic effects were unilateral, 
implying a principal first-pass removal, the possibility could be 
raised that FK506's immunosuppression might be relatively 
liver-specific, and consequently that much larger oral doses will 
be required for the successful transplantation of extrahepatic 
organs. A formal study of this latter question has not been 
made either with FK506, or with cyclosporine, which has been 
shown with the same Eck fistula model to have very similar 
characteristics (8). 
More interesting than such dose considerations is the possi-
ble beneficial effect of FK506 on hepatic repair. FK506 pro-
motes hypertrophy and hyperplasia, the ingredients of regen-
eration, and it has been shown by direct experimentation in 
rats to augment regeneration after partial hepatectomy (9). 
These effects are shared with cyclosporine (8-12), which has a 
TABLE 1. Hepatocyte size and Autoradiographic labeling 
Hepatocytes Size Units Labeled Hepatocytes/1000 Hepatocytes 
FK506 
n" (mg/kg/day) P left vs. P left va. Left 
right Right Left P vs. vehicle Right Left right Right Left P VB. vehicle Right 
Vehicle 6 .1l4±.007 0.4355 .1l2±.01l 4.45±.26 0.8429 4.42±.24 
0.01 12 .1l1±.008 0.0004 .100±.007 0.5782 0.1860 5.43±.35 0.0167 4.77±.60 0.0044 0.2477 
0.1 12 .137±.008 0.0000 .113±.006 0.0065 0.8351 5.98±.43 0.0001 5.19±.38 0.0005 0.0086 
1.0 10 .162+.012 0.0009 .134+.006 0.0004 0.0503 9.13±.89 0.0015 5.37±.78 0.0001 0.0510 
a In each experiment. samples were taken from 2 different right lobes and 2 different left lobes; n represents both samples, and the number of 
n 
animals is 2" . 
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TABLE 2. Area (I'M2) of endoplasmic reticulum (ER) per average midzonal hepatocyte 
Rough ER Smooth ER 
FK506 
n" (mg/kg/day) Left P left vs. Right Left P vs. vehicle Right Left P left vs. Right Left P vs. vehicle Right right right 
Vehicle 3 13874±1221 0.9672 13882±975 26416±3787 0.7996 26680±2202 
0.01 6 26332±1483 0.0001 18697±1010 0.0000 0.0019 18433±535 0.0000 23337±902 0.0661 0.1092 
0.1 6 29889±1117 0.0001 20325±975 0.0001 0.0007 18688±498 0.0018 22747±1305 0.0703 0.0725 
1.0 5 32091±1225 0.0002 20839±1612 0.0000 0.0003 17876±642 0.0024 23154±193 0.0574 0.0858 
" One sample from a right lobe and one from a left lobe were studied; n = number of animals. 
TABLE 3. Organelle volume (I'M3) in average midzonal hepatocytes 
Hepatocytes-mitochondria Hepatocytes-microbodies Hepatocytes-lysosomes Hepatocytes-lipids 
FK506 
n" (mg/kg/ day) Left P left vs. Right Left P left vs. Right Left P left VS. Right Left P left vs. Right 
right right right right 
Vehicle 3 178B.3±50B.4 0.7683 1657.6±164.5 207.0±22.6 0.0288 188.6±lB.5 229.0±62.7 0.6660 20B.0±29.1 94.0±16.7 0.6B83 9B.0±8.5 
0.Dl 6 1233.7±222.4 0.1903 1429.5±331.2 99.2±11.8 O.OOBO 173.8±39.6 62.3±15.1 0.0017 162.6±48.9 23.3±B.8 0.0012 81.0±15.1 
0.1 6 1288.5±236.2 0.2529 1439.3±115.4 86.3±11.5 0.0025 172.5±34.2 59.6±15.6 0.0000 187.6±14.B 22.B±6.7 0.0011 83.8±19.7 
1.0 5 1284.8±17B.9 0.1996 1440.6±31B.7 94.2±10.4 0.1111 136.6±41.3 48.8±1O.9 0.0002 160.0±23.8 15.6±2.8 0.0044 47.8±1l.3 
" One sample from a right lobe and one from a left lobe were studied; n = number of animals. 
completely different molecular structure. The experiments un-
derscore the possibility of using FK506 for the treatment of 
liver diseases, especially if there is an autoimmune component. 
The remarkable ability of FK506 to halt and reverse chronic 
rejection of liver allografts (3) may be a direct analogy to what 
can be achieved using this drug for nontransplant autoimmune 
disorders. There might even be the prospect of promoting 
hepatic healing in the absence of an immunologic pathogenesis. 
The implications of these experiments, together with recent 
advances in enzyme cheimstry, go far beyond the narrow issues 
that were examined in the present study. Cyc1osporine and 
FK506 act by inhibiting the synthesis and expression of inter-
leukin 2 and other cytokines (13, 14). Because both drugs are 
hepatotrophic as well as immunosuppressive, it was suggested 
that they might modulate hepatocyte growth control immuno-
logically (6, 9). However, other explanations are more plausible 
in light of recent information about the cytosolic binding sites 
of cyclosporine (cyclophilin) and FK506. While distinct, these 
binding sites have as a common constituent the enzyme cis-
trans peptidyl-prolyl isomerase (15, 16). This ubiquitous en-
zyme, which has been highly conserved throughout evaluation, 
catalyzes the isomerization of proline peptide bonds in oligo-
peptides and accelerates rate limiting steps in the folding of 
several proteins during their synthesis (17, 18). However, the 
physiologic significance ofPPlase was a mystery until one year 
ago when it was found to be the principal constituent of 
cyclophilin (19, 20) and later of the FK506 binding site (15, 
16). Rapamycin another T cell-specific immunosuppressive 
agent, has the same binding site as FK506 (15, 16). 
However, PPlase is found in many tissues, not just in lym-
phocytes, having first been discovered in the pig kidney (17). 
Pharmacologic inhibition of PPlase in heterogenous binding 
sites could explain why the nonimmunologic actions of cyc1o-
sporine and FK506 tend to alter the same clinical end-points 
although the mainfestations may differ quantitatively and may 
be in opposite directions (21). These include nephrotoxicity 
(less with FK506 than cyc1osporine), tendency to diabetes (the 
same with both drugs), hair growth (thinning may occur with 
FK506), cholesterol regulation (minimal with FK506), uric acid 
regulation (the same or less with FK506), and neurotoxicity. 
The neurotoxicity usually is not serious with either cyclospor-
ine or FK506, but it is remarkably similar with both drugs and 
includes tremors, paresthesias, headaches, increased sensitivity 
to light, mood changes, and insomnia. 
A clue about the reason for the neurologic manifestations 
has come from studies of mutant fruit flies (Drosophila) the 
heads of which contain an abnormally low amount of cyclo-
philinlike receptors as well as photoreceptors that are rhodop-
sin-deficient (18). On the basis of this genetic evidence, the 
authors suggested that correct folding and stability of the 
rhodopsin in photoreceptors cannot occur in the absence of the 
PPlase-rich cyc10philin receptors. 
Our hypothesis is that the foregoing array of clinical mani-
festations, the hepatotrophic affects described in the present 
communication, and the immunosuppression of both FK506 
and cyc1osporine all reflect the pharmacologically altered role 
of PPlase in various intracellular signal transduction processes. 
By working back from observations of both desired and unde-
sired effects of FK506, cyc1osporine, and other such agents, an 
understanding could be facilitated of the role in basic biology 
of what must be a heterogenous family of cytosolic binding 
sites which have in common PPlase activity. If the hepato-
trophic influence of agents like FK506 and cyc1osporine is not 
by a direct effect on the hepatocytes (6), it probably reflects 
the composite effect on altered receptors and second signals 
that remain to be delineated. 
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